HISUN Reports Favipiravir is Making Significant Difference Against COVID-19 in China

HISUN Reports Favipiravir is Making Significant Difference Against COVID-19 in China

Favipiravir (Avigan) has become a centerpiece to the Chinese response to COVID-19. Of course, good practices such as enforced lockdowns, masks, and strict social distancing rules all fall under the formula for success possibly combined with a more authoritarian governmental structure, which is used to enforce the pandemic rules. But the broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses certainly is helping according to recent press. As TrialSite News has reported, this drug has been approved in India, Russia and China, and the U.S. government via the Department of Defense (DOC) contributed over $200 million to its research and development. Why aren’t Americans benefiting from that investment?

As recently as 2015, the U.S. DOD funded a Phase 3 clinical trial to determine if a 5-day regimen of favipiravir reduced the time to alleviation of influenza symptoms, resolution of fever, and viral shedding, in subjects with uncomplicated influenza compared to no treatment. 

Zhejiang Hisun Pharmaceutical Co., Ltd (HISUN) secured a license to this now generic antiviral from Japanese maker FUJIFILM Toyama Chemical Co., Ltd.. (Toyama). The Chines...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee